WO2003006068A1 - Therapie genique pour le syndrome d'oeil sec - Google Patents
Therapie genique pour le syndrome d'oeil sec Download PDFInfo
- Publication number
- WO2003006068A1 WO2003006068A1 PCT/US2001/021785 US0121785W WO03006068A1 WO 2003006068 A1 WO2003006068 A1 WO 2003006068A1 US 0121785 W US0121785 W US 0121785W WO 03006068 A1 WO03006068 A1 WO 03006068A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- dihydrazide
- hyaluronic acid
- sequence
- bioconjugate
- Prior art date
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims abstract description 28
- 206010013774 Dry eye Diseases 0.000 title claims abstract description 28
- 238000001415 gene therapy Methods 0.000 title abstract description 7
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 126
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 115
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 113
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 107
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 107
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 107
- 238000000034 method Methods 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 239000000499 gel Substances 0.000 claims abstract description 22
- 239000004005 microsphere Substances 0.000 claims abstract description 19
- 239000011159 matrix material Substances 0.000 claims abstract description 16
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000017 hydrogel Substances 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 103
- 239000002773 nucleotide Substances 0.000 claims description 45
- 125000003729 nucleotide group Chemical group 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 238000004132 cross linking Methods 0.000 claims description 32
- 239000013612 plasmid Substances 0.000 claims description 27
- 239000004971 Cross linker Substances 0.000 claims description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 150000001718 carbodiimides Chemical class 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical group CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims 2
- 239000011363 dried mixture Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 108090000320 Hyaluronan Synthases Proteins 0.000 abstract description 85
- 102000003918 Hyaluronan Synthases Human genes 0.000 abstract description 65
- 239000000126 substance Substances 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 18
- 238000009472 formulation Methods 0.000 abstract description 15
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 abstract description 11
- 229940099552 hyaluronan Drugs 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000008279 sol Substances 0.000 abstract description 2
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 114
- 108020004414 DNA Proteins 0.000 description 89
- 235000018102 proteins Nutrition 0.000 description 37
- 210000001508 eye Anatomy 0.000 description 36
- 150000001413 amino acids Chemical class 0.000 description 29
- 239000000243 solution Substances 0.000 description 26
- -1 phosphotriesters Chemical class 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 14
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 14
- 239000005090 green fluorescent protein Substances 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 108010003272 Hyaluronate lyase Proteins 0.000 description 12
- 102000001974 Hyaluronidases Human genes 0.000 description 12
- 229960002773 hyaluronidase Drugs 0.000 description 11
- 238000012546 transfer Methods 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 235000012431 wafers Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 210000000795 conjunctiva Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000002381 testicular Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000008174 sterile solution Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 3
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 3
- 101710128038 Hyaluronan synthase Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 101100340145 Mus musculus Has2 gene Proteins 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100340138 Mus musculus Has1 gene Proteins 0.000 description 2
- 101100396080 Mus musculus Has3 gene Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000004017 vitrification Methods 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150027313 Has2 gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 108050009363 Hyaluronidases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- LVGDWMXFPHBFBW-UHFFFAOYSA-N [hydrazinyl(oxido)phosphaniumyl]hydrazine Chemical class NNP(=O)NN LVGDWMXFPHBFBW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000010556 emulsion polymerization method Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical class NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- ACOJCCLIDPZYJC-UHFFFAOYSA-M thiazole orange Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C(C=C3N(C4=CC=CC=C4S3)C)=CC=[N+](C)C2=C1 ACOJCCLIDPZYJC-UHFFFAOYSA-M 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 229950000329 thiouracil Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to the use of derivatized hyaluronic acid/nucleic acid
- compositions preferably dihydrazide derivatized hyaluronic acid/nucleic acid compositions, and
- microsphere, film, wafer, matrix, gel and sol formulations comprising these compositions.
- compositions of the invention also relates to the use of the compositions of the invention, preferably, wherein the
- nucleic acid is a hyaluronan synthase (HAS) gene, in gene therapy applications to treat dry eye
- HAS hyaluronan synthase
- Dry eye is a chronic condition characterized, simplistically, by a paucity of
- the cause of dry eye can be infectious disease, the aging process,
- eye include scarcity of moisture and lubrication or tear film, itching, burning, inflammation,
- the tear film of the eye protects ocular tissues by providing moisture and lubrication. It is composed of three major components: water (whose primary source is the
- the tear volume may be determined by the
- ter test This is a test using a filter paper strip with graduations. The strip is placed at the
- the distance the tear fluid travels determines whether the
- Dry eye syndrome is a common, chronic condition. It is defined and clinically
- lacrymal gland dysfunction can all result in dry eye. Thus, there is not one, but many causes,
- HA hyaluronic acid
- Hyaluronic acid has been shown to be anti-inflammatory and to stimulate the growth of
- HA corneal epithelial cells in in vitro and in in vivo tests.
- HA is also lubricious and hygroscopic.
- Hyaluronan synthase (HA synthase) is the enzyme that synthesizes hyaluronic acid
- the enzyme is found in the cell membrane and extrudes polymerized sugar
- HA synthase (HAS1, HAS2, and HAS3) that differ in catalytic activity and in the type of
- HA is a component of the tear film, and has anti-inflammatory and lubricating properties, enhancement of HA secretion in the eye of dry eye patients is of clinical
- One way to enhance HA secretion is by transfection of the tissues of the eye with HA
- tear film This provides relief of the symptoms of dry eye which is longer-lived than that provided by therapies which are currently available.
- the HAS 1-3 genes encode a family of proteins which are highly conserved in
- HAS 1-3 homologues which are known in the art.
- the numbers represent the percentage of nucleotide/amino acid identity or
- SEQ ID NO. 1 Mouse HAS1 DNA
- SEQ ID NO. 2 Mouse HAS2 DNA
- SEQ ID NO. 3 Mouse HAS3 TmA
- SEQ ID NO. 4 Mouse HAS 1 Protein
- SEQ ID NO. 5 Mouse HAS2 Protein
- SEQ ID NO. 6 Mouse HAS3 Protein
- the number on the left indicates the level of sequence identity between the specified sequences and the number to the right specifies the level of sequence homology between the specified sequences.
- the present invention relates to a method for transfecting a cell (in cell culture or
- nucleic acid e.g. , plasmid DNA
- hyaluronan a nucleic acid (e.g. , plasmid DNA), preferably hyaluronan
- nucleic acid has a nucleotide sequence of about 70% to about 100% identity to a reference
- nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-3 or wherein the
- nucleic acid has a nucleotide sequence which encodes a hyaluronan synthase enzyme (e.g, HAS 1 -
- amino acid sequence of the enzyme comprises about 70% to about 100% homology or identity to a reference amino acid sequence selected from the group consisting of
- a derivatized hyaluronic acid/nucleic acid bioconjugate which comprises said nucleic acid or, preferably, with a dihydrazide derivatized hyaluronic acid/nucleic acid bioconjugate comprising hyaluronic acid crosslinked with adipic dihydrazide wherein the adipic dihydrazide is further crosslinked to the nucleic acid.
- the method is used in the
- the present invention also includes the above-described
- the invention also includes a method of producing a dihydrazide derivatized hyaluronic acid/nucleic acid bioconjugate comprising;
- nucleic acid comprises a nucleotide sequence of at least
- hyaluronan synthase protein comprising an amino acid sequence which has about 70% to about
- step (d) adjusting the pH of the suspension of step (c) to the acidic range and
- incubating the mixture for a period of time e.g., 6 hours, 24 hours, or 48 hours;
- step (e) isolating the suspended material from the suspension of step (d); and (f) washing the isolated material from step (e) with an alcohol.
- cross linking maybe increased by increasing the incubation period of step (d) or decreased by
- step (d) decreasing the incubation period of step (d).
- the extent of crosslinking may also be increased by further decreasing the pH at step (d) or decreased by raising the pH at step (d). Increasing the extent of crosslinking
- the concentration will decrease the extent of crosslinking.
- lyophilization is performed after cross linking in step (d).
- FIGURE 1 A representative HAS construct containing the HAS2 gene, a CMV
- FIGURE 2 The expression of green fluorescent protein (GFP) in the conjunctiva
- FIGURE 3 The expression of green fluorescent protein in the conjunctiva of
- FIGURE 4 The expression of green fluorescent protein in the conjunctiva of
- FIGURE 5 Schematic diagram of formulation steps for HA-DNA films
- Microspheres were made using an emulsion polymerization method by mixing HA
- microspheres were weighed and resuspended in physiological phosphate saline buffer. Bovine testicular hyaluronidase was added (e.g., 1 unit/ ml) as appropriate. At the indicated time
- DNA was quantified using a thiazole orange assay by measuring the fluorescence of DNA bound
- FIGURE 7 Chemical structures of dihydrazides which may be used in the present invention.
- FIGURE 8 ADH cross-linked, lyophilized, HA-DNA matrices. Left: low power
- FIGURE 9 Three formulations of cross-linked HA/DNA matrices.
- the invention relates to the introduction of hyaluronan synthase genes to tissues
- Hyaluronan synthase is an enzyme that causes the
- HAST, HAS2 and HAS3 are the products of 3 distinct but related genes (HAST, HAS2 and HAS3).
- HAS 1-3 hyaluronan synthase genes
- HAS 1-3 synthases
- hyaluronan synthase refers to any enzyme or gene encoding an enzyme which comprises hyaluronan synthase activity.
- hyaluronan synthase is derived from
- a protein may comprise hyaluronan synthase activity if said
- Hyaluronan synthase assays are discussed below.
- the HAS gene encodes the form of the enzyme that synthesizes HA and secretes
- the invention uses hyaluronan synthase genes and
- bioconjugate In these bioconjugates, the nucleic acid is crosslinked to the derivatized hyaluronic
- the hyaluronic acid is dihydrazide derivativized, more preferably the hyaluronic
- bioconjugate allows for the sustained delivery
- the nucleic acid may be any nucleic acid into the surrounding mileau. Once released from the biconjugates, the nucleic acid may
- nucleic acid wherein a nucleic acid is crosslinked to derivatized hyaluronic acid may be referred to as a " derivatized hyaluronic acid/nucleic acid bioconjugate", “cross-linked HA", “DNA/HA bioconjugate” or “bioconjugate”.
- the biconjugates of the invention comprise a "dihydrazide derivativized hyaluronic acid/nucleic acid bioconjugate". These terms include all formulations of this composition including microspheres, films, wafers, matrices, gels, sols and
- patient or "subj ect” refers to any organism, preferably an animal, more preferably a mammal and most preferably a human.
- a “DNA molecule”, “nucleic acid molecule” or “nucleic acid” refers to the phosphodiester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules”) or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine , or deoxycytidine; "DNA molecules”), or any phosphoester analogs thereof, such as phosphorothioates and thioesters, in either single stranded form, or a double-stranded helix.
- nucleic acid molecule and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms or to any particular
- oligonucleotide refers to a nucleic acid molecule of 20 bases
- a "recombinant DNA molecule” is a DNA molecule that has undergone a
- a "DNA sequence” or “nucleotide sequence” is a series of nucleotide bases (also
- nucleotides in DNA and RNA, and means any chain of two or more nucleotides.
- nucleotide sequence typically carries genetic information, including the information used by
- DNA or cDNA DNA or cDNA, RNA, any synthetic and genetically manipulated nucleic acid, and both sense and
- anti-sense nucleic acids This includes single- and double-stranded molecules, i.e. , DNA-DNA,
- DNA-RNA and RNA-RNA hybrids as well as “protein nucleic acids” (PNA) formed by PNA.
- PNA protein nucleic acids
- conjugating bases to an amino acid backbone This also includes nucleic acids containing
- modified bases for example thio-uracil, thio-guanine and fluoro-uracil.
- protein refers to any peptide or polypeptide containing two or more amino acids, modified amino acids, or amino acid derivatives.
- Protein by way of example, and without excluding other types of proteins, includes enzymes (e.g., HAS 1-3) and structural
- heterologous refers to a combination of elements not naturally occurring.
- heterologous DNA refers to DNA not naturally located in the cell, or
- the heterologous DNA includes a gene foreign to
- a heterologous expression regulatory element is such an element operatively associated
- nucleic acids and “nucleic acid molecules” herein maybe flanked by natural
- regulatory (expression control) sequences may be associated with heterologous sequences,
- promoters including promoters, internal ribosome entry sites (IRES) and other ribosome binding site
- nucleic acids may also be any nucleic acids, introns, 5'- and 3'- non-coding regions, and the like.
- the nucleic acids may also be any nucleic acids, introns, 5'- and 3'- non-coding regions, and the like.
- the nucleic acids may also be any nucleic acids, introns, 5'- and 3'- non-coding regions, and the like.
- the nucleic acids may also be any nucleic acids
- a dihydrazide e.g., adipic
- Nucleic acids may contain one or more additional covalently
- linked moieties such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal
- nucleic acids may be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl phosphoramidate linkage.
- nucleic acids herein may also be modified with a label capable of providing a detectable signal, either directly or indirectly.
- Exemplary labels include
- radioisotopes fluorescent molecules, biotin, and the like.
- host cell means any cell of any organism that is selected, modified,
- a host ocular cell is transfected with a hyaluronan synthase gene (e.g. , HAS1-3)
- Proteins are made in the host cell using instructions in DNA and RNA, according to
- RNA sequence having instructions for a particular protein or enzyme is "transcribed" into a corresponding sequence of RNA.
- the RNA sequence in turn is
- nucleotide triplet or codon AAA can be coded by the nucleotide triplet or codon AAA or by the codon AAG. Codons
- translation stop signals e.g., TGA, TAG or TAA. Because the nucleotides in
- DNA and RNA sequences are read in groups of three for protein production, it is important to begin reading the sequence at the correct nucleotide, so that the correct triplets are read.
- gene refers to a DNA sequence that encodes or corresponds to a particular sequence of amino acids that comprise all or part of one or more proteins, and may or
- gene also includes DNA sequences which are transcribed from DNA to RNA, but are not translated into
- a "coding sequence” or a sequence “encoding” an expression product such as a
- RNA, polypeptide, or protein is a nucleotide sequence that, when expressed, results in the
- RNA, polypeptide, or protein i.e., the nucleotide sequence encodes an amino acid sequence for that polypeptide or protein.
- a coding sequence for a protein may include a
- a nucleic acid may also "encode” a gene or DNA
- nucleotide sequence of the gene or DNA sequence is contained within the
- a "promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell or in vitro and initiating transcription of a downstream (3 1 direction) coding
- a promoter sequence is bounded typically at its 3' terminus by the transcription
- initiation site and extends upstream (5' direction) to include bases or elements necessary to
- RNA polymerase domains responsible for the binding of RNA polymerase.
- a coding sequence may be "under the control of, "operatively associated with”
- RNA polymerase transcribes the coding sequence into mRNA, which may then be spliced
- a DNA sequence is expressed in or by a cell to form an "expression product" such as a protein.
- the expression product itself e.g. the resulting protein, may also be said to be
- An expression product can be characterized as intracellular, extracellular or secreted.
- intracellular means something that is inside a cell.
- extracellular means something that is outside a cell.
- a substance is “secreted” by a cell if it appears in significant measure outside the cell, from somewhere on or inside the cell.
- gene transfer refers broadly to any process by which nucleic acids are
- gene therapy refers to the use of a gene transfer
- HAS gene (e.g., HASl, 2 or 3) into the cells of a subject (e.g., ocular cells) constitutes a gene transfer. Transfer of a HAS gene into the ocular cells of a patient for the purpose of treating DES
- transfection or "transformation” means the introduction of a foreign
- nucleic acid into a host cell by any means. Transfection or transformation may cause the host
- the introduced gene or sequence typically a protein coded by the introduced gene or sequence.
- telomere may also be called a "cloned” or “foreign” gene or sequence and may include regulatory or
- control sequences such as start, stop, promoter, signal, secretion, or other sequences used by a
- the gene or sequence may include nonfunctional sequences or sequences with no known function.
- the DNA or RNA introduced to a host cell can come from any source, including cells of the same genus or species as the host cell, or cells of a different
- vector means the vehicle by which a DNA or RNA sequence (e.g., a
- foreign gene can be introduced into a host cell, so as to transform or transfect the host.
- Transformation or transfection may promote expression (e.g., transcription and translation) of the introduced sequence.
- Vectors may include plasmids (e.g., pcDNA 3.1/HisC12-13).
- Vectors typically comprise the DNA of a transmissible agent, into which foreign
- DNA is inserted.
- a common way to insert one segment of DNA into another segment of DNA involves the use of enzymes called restriction enzymes, which cleave DNA at specific sites
- restriction sites specifically groups of nucleotides
- DNA ligase which joins pieces of
- DNA such as a restriction enzyme digested nucleic acid and a restriction enzyme digested
- a "cassette” refers to a DNA coding sequence or segment of DNA that
- the cassette restriction sites are designed to ensure insertion of the cassette in the proper reading
- segment or sequence of DNA having inserted or added DNA such as an expression vector
- Plasmid also be called a "DNA construct.”
- a common type of vector is a "plasmid”, which generally is
- a plasmid vector often contains coding DNA and promoter DNA and has one or more restriction
- Promoter DNA and coding DNA may be from the same gene or from different genes, and may be from the same or different organisms.
- a large number of vectors, including plasmid and fungal vectors, have been described for replication and/or expression in a variety of eukaryotic and prokaryotic hosts.
- Non- limiting examples include pcDNA3.1, pcDNA/HisC 12-13, pKK plasmids (Clonetech), pUC plasmids, pET plasmids (Novagen, Inc., Madison, WT), pRSET or pREP plasmids
- Recombinant cloning vectors will often include one or more
- replication systems for cloning or expression one or more markers for selection in the host, e.g.
- sequence identity refers to exact matches between the two sequences
- proteins may be determined by use of a BLASTP or CLUSTALW sequence comparison
- sequence similarity As used herein, the term “sequence similarity”, “similarity”, “sequence homology”
- proteins may be determined using a CLUSTALW or BLASTP algorithm. A conserved match
- threonine, tyrosine, serine, glycine no charge/hydrophilic (cysteine, asparagine, glutamine, threonine, tyrosine, serine, glycine); aromatic (tryptophan, tyrosine, phenylalanine); negatively charged/hydrophilic (aspartic acid, glutamic acid); positively charged/hydrophilic (histidine, lysine, arginine).
- BLAST ALGORITHMS BLAST ALGORITHMS
- the present invention includes bioconjugates which comprise nucleic acids comprising a hyaluronan synthase gene (i.e., a gene comprising hyaluronan synthase activity),
- the nucleic acid comprises a nucleotide sequence of at least about 70% identity to a
- the encoded amino acid sequence comprises at least about 70% homology or identity to a sequence selected from the group consisting of SEQ ID NOs. 4-6, (preferably at
- parameters of the algorithms are selected to give the largest match between the respective
- the level of identity or homology mentioned above is greater than about
- the present invention also includes bioconjugates which comprise nucleic acids comprising a hyaluronan synthase gene comprising a nucleotide sequence of at least about 70% identity to a reference nucleotide sequence of any hyaluronan synthase gene disclosed in U.S.
- hyaluronan synthase proteins comprising amino acid sequences with at least about 70%) homology or identity to the hyaluronan synthase protein amino acid sequences
- the level of identity or homology mentioned above is greater than about 70%, preferably about 80% or greater, more
- induce'Or induction refers to an increase by a measurable amount.
- hyaluronic acid which has been derivatized with a dihydrazide; a nucleic acid
- a dihydrazide modified hyaluronic acid in which a pendent hydrazide moiety is still available for reaction may be referred to as a hydrazido hyaluronic acid.
- a hydrazido hyaluronic acid Alternatively, a
- any chemical crosslinker e.g., carbodiimides
- any chemical crosslinker e.g., carbodiimides
- acid/nucleic acid bioconjugate of the invention may include hyaluronic acid which is crosslinked to a dihydrazide wherein the a dihydrazide portion of the molecule is further crosslinked to a nucleic acid.
- Adipic dihydrazide is the preferred dihydrazide with which to derivatize hyaluronic acid, however, other dihydrazide molecules may be used for this purpose (see FIGURE 7).
- Said nucleic acids may be in the form of linear DNA, oligonucleotides or RNA, however, in a preferred embodiment, the nucleic acid is plasmid DNA. Accordingly, a preferred embodiment
- bioconjugates comprising plasmid DNA conjugated to adipic dihydrazide derivatized hyaluronic acid.
- the bioconjugates of the invention may be further
- bioconjugates of the invention may be further conjugated to ligands which allow the bioconjugates to be targeted to a particular location in the subject's
- this location may comprise a particular type of cell such as conjunctival cells
- the additional conjugates may be used to prevent or
- R is any compound.
- ethyl-, propyl-, isopropyl-, butyl-, pentyl-, hexyl-, heptyl-, or octyl) are preferred, however other
- dihydrazides are within the scope of the invention, such as sulfonodihydrazides and
- FIGURE 7 illustrates non- limiting examples of preferred dihydrazides that may be used in the present invention.
- the carbodiimide used in the present invention comprise ED AC (l-ethyl-3-(3-dimethyl-
- moiety refers to a chemical entity which may be a part, portion or
- crosslinked or “conjugated” refers to the attachment of two substances via any type of bond or force.
- substances may include covalent bonds, ionic bonds or hydrogen bonds, van der Waals forces,
- Nucleic acids can be released from
- cross-linked HA microspheres films, wafers, matrices, hydrogels, gels, sols, or any other form
- gel is intended to refer to viscous or semi-solid and jelly-like material.
- hydrogel is intended to mean macromolecular networks, which swell in water.
- film is intended to mean macromolecular networks, which swell in water.
- matrix is intended to mean a substance formed by lyophilizing a gel.
- microsphere refers to microscopic particles used to deliver substances, such as nucleic
- microspheres of this invention may have a diameter (e.g., less than
- microspheres of the invention are between
- microspheres of any size wherein the essential elements of the present invention are preserved are preserved
- a wafer is a matrix like structure which generally has a
- the derivatized hyaluronic acid/nucleic acid bioconjugates may include any gene. Preferred embodiments include a gene which produces hyaluronic acid or produces a substance which
- this gene causes the production of hyaluronic acid; in preferred embodiments, this gene is hyaluronan
- hyaluronic acid/nucleic acid bioconjugates that include said genes may also include, within the nucleic acid that contains the gene, additional
- nucleotides whose sequence causes expression of a protein or RNA, which corresponds to the
- bioconjugates which include derivatized hyaluronic acid that is
- nucleic acids may be produced by any means which yields nucleic acids of sufficient quality and purity so as to allow the successful practice of the invention.
- nucleic acids may be produced by any means which yields nucleic acids of sufficient quality and purity so as to allow the successful practice of the invention.
- nucleic acids may be produced by any means which yields nucleic acids of sufficient quality and purity so as to allow the successful practice of the invention.
- nucleic acids may be produced
- conjugate of hyaluronic acid and nucleic acid gels or hydrogels may be topically applied for sustained gene transfer.
- formulations may be produced
- physiological buffer usually contain a physiological buffer and/or salts such as sodium chloride, sugars such as
- HA-DNA solution containing the appropriate gene
- the dosage unit could be extracted and packaged using conventional blister packaging
- packaged dosage forms may be sterilized by an appropriate method (e.g., ETO, EB, gamma irradiation).
- the dosage form may be manufactured by an aseptic batch process using sterile (filter sterilized) solutions of reagents and hyaluronan.
- sterile solution is
- lyophilization processes are routinely practiced by the pharmaceutical and medical device industries.
- the sterile, packaged dosage form is stored at room temperature. At the point of use, the package is opened and the dosage form is rehydrated with an appropriate ophthalmic solution. It is then placed in or on the eye in an appropriate position that will allow gene transfer
- solid dosage forms such as films, wafers and matrices may be
- a suitable solvent such as buffers or solutions routinely used in ophthalmic practice prior to implantation (e.g., distilled water, phosphate buffer and/or
- Sols or gels may be applied using syringes, droppers or other devices capable of
- Microspheres if dried or lyophilized, maybe
- solvents e.g., distilled water phosphate buffer and/or saline
- the biconjugate may be placed between the eye and conjunctiva for a period of time which is sufficient to allow a gene transfer process to occur (e.g., 1 hour, 5 hours or 10
- the bioconjugate may be placed directly over the surface of the eye, after
- the eye lid may be closed and covered with a patch.
- the bioconjugates may be allowed to incubate for an extended period (e.g., 12 or 24 hours), after which the patch
- the eye lid may be opened.
- bioconjugates of the invention is given to a patient.
- the dose given to the patient is sufficient to cause a therapeutic effect.
- patients may require a large amount of new hyaluronan to be produced.
- a physician may apply two doses simultaneously to increase the number of eye cells transfected, or administer the standard dose more frequently.
- the derivatized hyaluronic acid/nucleic acid bioconjugates of the invention may
- DES used in the treatment of DES may comprise an expression plasmid (a closed, circular piece of
- the promoter may be a human tissue specific promoter which will function in the target
- a promoter which may be used in this invention is an epithelial cell promoter (e.g. , the ED-LEE promoter), a human papilloma virus promoter, a B2LF 1 promoter from Epstein
- the construct may also have enhancer
- nucleic acid is then available for uptake by the target eye cells.
- FIGURE 1 An example of an experimental construct which may be used to express hyaluronan synthase in cells is shown in FIGURE 1.
- Expression of the gene in the ocular tissues will increase the hyaluronic acid content of the tear film of the eye. This will ease the symptoms of dry eye.
- Another aspect relates to the provision of genes to other tissues of the eye that would benefit from localized therapy. Diseases of the retina, for example, could be treated by
- angiogenesis for the treatment of macular degeneration or genes related to lipid biosynthesis that
- the present invention may be used to treat medical conditions of the eye wherein delivery of a nucleic acid to the cells of the eye would have a desirable therapeutic effect.
- eye refers to the visual organ as commonly known including all
- eye includes, but is not limited to, epithelial
- the cells of the conjunctiva are
- bioconjugates of the present invention are useful reagents
- any cell preferably a eukaryotic cell, more preferably a human eye cell (e.g, a conjunctival or corneal epithelial cell) with a nucleic acid which, preferably,
- the nucleic acid has a nucleotide sequence of
- nucleic acid consisting of SEQ ED NOs. 1-3 or wherein the nucleic acid has a nucleotide sequence which encodes a hyaluronan synthase enzyme (e.g, HAS 1 -3), preferably the amino acid sequence of the
- enzyme comprises about 70% to about 100% homology or identity to a reference amino acid sequence selected from the group consisting of SEQ ED NOs.4-6 wherein homology is
- the bioconjugates provide a means by which a nucleic acid may be gradually
- bioconjugate is degraded, the nucleic acid portion of the bioconjugate is liberated and made available for uptake by the host cells.
- the host cells are used for in vitro cell transformation.
- liposome mediated conjugates instead of, or in addition to, free, unconjugated, nucleic acids.
- transformation protocols using the bioconjugates may include seeding a 35 mm plate with about
- a mixture comprising the bioconjugates (e.g, comprising l ⁇ g or more
- hyaluronidase e.g, 10, 15, 20, or 25 units/ml bovine testicular hyaluronidase
- cationic liposomes e.g., lipofectin
- hyaluronidase is believed to degrade the hylauronic acid of the bioconjugate and release the
- the rate at which the nucleic acid is released may be modulated by controlling the
- Hyaluronic acid determination One way to determine the level of hyaluronan synthase activity in a cell is to determine the level of hyaluronic acid in the cell. Cells with a
- high level of hyaluronan synthase activity may comprise a high level of hyaluronic acid.
- level of hyaluronan synthase activity which is associated with a given gene or protein e.g., human, Xlaevis, B. taurus, M.musculus, R. norvegicus or G.gallus, HASl, HAS2
- HAS3 can be determined by introducing the gene (e.g., by use of the bioconjugates of the
- the level of hyaluronic acid in the cell may be compared to that of a cell into which a
- Hyaluronic acid production, in cells which have been transformed with the bioconjugates of the invention, may be determined by measuring the
- hyaluronic acid in a transformed cell maybe measured by a Particle
- the Assay includes contacting transformed cells with fixed and suspended
- the erythrocytes may be obtained commercially. After the cells are allowed to settle
- Hyaluronic acid production by transformed cells may also be measured by a Biotinylation Reporter Assay.
- transformed cells are contacted with biotinylated
- biotin-HABP Hyaluronic Acid Binding Protein
- Biotin-HABP will bind to
- streptavidin conjugated alkaline phosphatase in added to the biotin-HABP bound cells and an alkaline phosphatase substrate is added.
- streptavidin moiety of streptavidin conjugated alkaline phosphatase will be described in detail below.
- biotin-HABP-streptavidin-alkaline phosphatase complex binds to the biotin moiety of biotin-HABP on the surface of the cells.
- the presence of the biotin- HABP-streptavidin-alkaline phosphatase complex on the cells will be apparent when alkaline phosphatase catalyzes the substrate to produce a colored product.
- the substrate forms an insoluble product, when catalyzed by alkaline phosphatase, which deposits on the surface of
- the color change may be observed microscopically or it can be measured colorimetrically in a clear plastic microtiter plate using a microplate reader.
- Hyaluronan synthase activity may also be determined using the assays disclosed
- Another aspect relates to the commercial feasibility of manufacture of the
- aqueous solution of HA is mixed with the DNA, preferably a
- the pH of the solution is adjusted to an acidic range below 7, and preferably between about 1 to about 5, and the HA-DNA mixture
- FIGURE 5 illustrates a flow chart depicting the method described above. Gels and sols having approximately 97-99.5% (w/v) water content are made by
- Matrices and wafers are made by either mixing all of the
- One aspect of the invention relates to the control of the release of DNA by the
- linking can be controlled by the concentration of the reactants, the pH of the reaction mix, the
- the extent of crosslinking may be increased by decreasing the pH of the
- crosslinking reaction extending the period of time for which the hyaluronic acid is allowed to crosslink in the presence of crosslinker or by increasing the concentration of the crosslinking reagent (e.g., the dihydrazide) in the reaction.
- the extent of crosslinking may be decreased by increasing the pH of the crosslinking reaction, shortening the period of time for which the hyaluronic acid is allowed to crosslink in the presence of crosslinker or by decreasing the concentration of the crosslinking reagent in the crosslinking reaction.
- FIGURE 9 demonstrates that DNA/HA matrices including HA incubated in the presence of crosslinker for 6 hours (#2) are less refractory to degradation and release of DNA than that of
- matrices including HA crosslinked for 12 hours (#1) or 24 hours (#3).
- the release of DNA can also be controlled by using a variety of cross-linkers
- dihydrazide produces gels that are more easily degraded.
- the kinetics of DNA release can be
- DNA can be evaluated.
- the assay described in this invention can also be performed in the
- the method of drying is lyophilization. Lyophilization refers to the process of freezing a liquid and drying it
- EXAMPLE 1 EXPRESSION OF MURINE HYALURONAN SYNTHASE GENES IN
- HAS2 and HAS3 in mammalian cells were prepared as follows. Plasmids encoding
- mouse hyaluronan synthase cDNAs HAS2 SEQ TD NOs: 2 and 5; Spicer et al, J. Biol.
- the insert DNA was purified from the gel slices by solubilizing in a chaotropic buffer, binding to a commercially available (Qiagen;
- silica matrix spin filter followed by elution with a Tris buffer at pH8.5.
- primers were designed to conserve the previously inserted optimized Kozak initiation sequence
- thermostable polymerase pfu Turbo, Stratagene; La Jolla, CA
- the resulting PCR products were analyzed by gel electrophoresis and purified (Qiagen; Valencia, CA). All four sets of PCR products were digested sequentially with Xhol and BamH ⁇ ,
- the vector was double cut with
- V5 is a viral epitope engineered
- the volume of the solution was about 90 % of the final volume to allow for the addition
- the DNA expression plasmid of EXAMPLE 1 was added and mixed well at slow speed (about 100 rpm). To effect a 1% weight per volume loading, 10 mg of DNA was added
- the liquid mixture may be dispensed into a mold that will contain one dose or multiple doses of the therapeutic. Alternatively, the mixture may be placed into a mold that will
- cross-linker e.g., adipic dihydrazide or ADH
- each mixing step was performed for 10 minutes. If buffers are not present, the
- pH will be slightly basic after addition of reagents and prior to acidification. Because the release
- genes can be modulated by the degree of cross-linking, this step can be varied.
- the lyophilized matrices are cross-linked for 6 hours. This will enable a relatively long term
- the cross-linking step can be performed for sustained gene delivery.
- the cross-linking step can be performed for sustained gene delivery.
- the matrices maybe extracted with alcohol while still within the
- the molds by introducing the alcohol to the mold, and allowing the matrix to "soak" in the alcohol solution for the required amount of time.
- the alcohol is removed by aspiration and the process is repeated 4 times. After extraction of reagents as depicted in the flow chart, the matrices are
- the extracted matrix maybe packaged as other ophthalmic products; for example,
- FIGURE 1 An electron micrograph of a matrix produced by this method is shown in FIGURE
- hyaluronic acid bioconjugate maybe transferred to living rat ocular cells and that the transformed ocular cells may express functional GFP.
- the GFP gene was functionally associated with a promoter which can cause
- FIGURES 2-4 Micrographs showing GFP fluorescence in the rat eyes are shown in FIGURES 2-4.
- the GFP allele used in the experiment had a short half life of only 2-4 hours and yet GFP fluorescence was observed for an extended period after initial transfer of the gene.
- human corneal epithelial cells are transformed with matrices of
- the invention comprising mouse HASl , HAS2 or HAS3. Furthermore, expression of hyaluronic
- mice HASl SEQ ED NO.1
- mouse HAS2 SEQ ED NO.2
- mouse HAS 3 SEQ ED NO.3
- pcDNA3.1/V5-His A invitrogen; Carlsbad, CA
- Hyaluronic acid production is then determined for each transformed cell line.
- plasmid pcDNA3.1/V5-His A (Invitrogen; Carlsbad, CA) which drives expression of the HAS 1, HAS2 or HAS 3 genes from a CMV promoter.
- Matrices comprising each plasmid are
- Human corneal epithelial cell lineHCE-2 (CRL-11135;ATCC,
- Solution A Dilute DNA/HA matrix bioconjugates in 1 OO ⁇ l serum-free medium ( OPTI-MEM,
- Solution B For each transfection, dilute 2-25 ⁇ l of LEPOFECTAMENE Reagent into 1 OO ⁇ l of the
- Solutions A and B are combined and mixed gently, and incubate at room
- Hylauronic acid determination The quantity of hyaluronic acid associated with
- each cell line is determined using the biotin/streptavidin/horse radish peroxidase conjugated assay discussed below.
- the transformed cells are fixed and incubated for 1 hour with
- HABP biotinylated hyaluronic acid binding protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2001/021785 WO2003006068A1 (fr) | 2001-07-10 | 2001-07-10 | Therapie genique pour le syndrome d'oeil sec |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2001/021785 WO2003006068A1 (fr) | 2001-07-10 | 2001-07-10 | Therapie genique pour le syndrome d'oeil sec |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003006068A1 true WO2003006068A1 (fr) | 2003-01-23 |
Family
ID=21742693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/021785 WO2003006068A1 (fr) | 2001-07-10 | 2001-07-10 | Therapie genique pour le syndrome d'oeil sec |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003006068A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982298B2 (en) | 2003-01-10 | 2006-01-03 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
WO2006010066A3 (fr) * | 2004-07-09 | 2006-07-20 | Cleveland Clinic Foundation | Reseau macromoleculaire reticule de hydroxyphenyle et applications associees |
US7465766B2 (en) | 2004-01-08 | 2008-12-16 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US8080260B2 (en) | 2008-02-13 | 2011-12-20 | The Cleveland Clinic Foundation | Molecular enhancement of extracellular matrix and methods of use |
US8138265B2 (en) | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US8137688B2 (en) | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US8410180B2 (en) | 2008-04-30 | 2013-04-02 | The Cleveland Clinic Foundation | Methods to treat urinary incontinence |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652347A (en) * | 1993-11-30 | 1997-07-29 | The Research Foundation Of State University Of New York | Method for making functionalized derivatives of hyaluronic acid |
WO1997040174A1 (fr) * | 1996-04-22 | 1997-10-30 | Leukosite, Inc. | Hyaluronan synthetases de mammifere, acides nucleiques et leurs utilisations |
WO1998000551A2 (fr) * | 1996-07-03 | 1998-01-08 | Mayo Foundation For Medical Education And Research | Gene codant la synthase hyaluronan |
WO2000078357A2 (fr) * | 1999-06-18 | 2000-12-28 | The Collaborative Group, Ltd. | Pellicule d'acide hyalonurique et matrice pour transfert prolonge de genes |
US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
-
2001
- 2001-07-10 WO PCT/US2001/021785 patent/WO2003006068A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652347A (en) * | 1993-11-30 | 1997-07-29 | The Research Foundation Of State University Of New York | Method for making functionalized derivatives of hyaluronic acid |
WO1997040174A1 (fr) * | 1996-04-22 | 1997-10-30 | Leukosite, Inc. | Hyaluronan synthetases de mammifere, acides nucleiques et leurs utilisations |
WO1998000551A2 (fr) * | 1996-07-03 | 1998-01-08 | Mayo Foundation For Medical Education And Research | Gene codant la synthase hyaluronan |
US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
WO2000078357A2 (fr) * | 1999-06-18 | 2000-12-28 | The Collaborative Group, Ltd. | Pellicule d'acide hyalonurique et matrice pour transfert prolonge de genes |
Non-Patent Citations (2)
Title |
---|
ITANO ET AL.: "Hyaluronan synthase: New directions for hyaluronan research", TRENDS GLYCOSCI. GLYCOTECH., vol. 10, no. 51, January 1998 (1998-01-01), pages 23 - 38, XP002949117 * |
USUI ET AL.: "Hyaluronan synthase expression in bovine eyes", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 40, no. 3, March 1999 (1999-03-01), pages 563 - 567, XP002949118 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982298B2 (en) | 2003-01-10 | 2006-01-03 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US7368502B2 (en) | 2003-01-10 | 2008-05-06 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US8021350B2 (en) | 2003-01-10 | 2011-09-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US8138265B2 (en) | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US8137688B2 (en) | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US8207262B2 (en) | 2003-01-10 | 2012-06-26 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US7465766B2 (en) | 2004-01-08 | 2008-12-16 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
WO2006010066A3 (fr) * | 2004-07-09 | 2006-07-20 | Cleveland Clinic Foundation | Reseau macromoleculaire reticule de hydroxyphenyle et applications associees |
US8080260B2 (en) | 2008-02-13 | 2011-12-20 | The Cleveland Clinic Foundation | Molecular enhancement of extracellular matrix and methods of use |
US8410180B2 (en) | 2008-04-30 | 2013-04-02 | The Cleveland Clinic Foundation | Methods to treat urinary incontinence |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2351593C (fr) | Greffage de polymeres par polysaccharide synthases | |
JP6159359B2 (ja) | 自己組織化ペプチドおよび高強度ペプチドゲル | |
ES2616263T3 (es) | Fabricación de N-acetilgalactosamina-6-sulfatasa humana, altamente fosforilada, activa, y usos de la misma | |
Zarembinski et al. | Thiolated hyaluronan-based hydrogels crosslinked using oxidized glutathione: An injectable matrix designed for ophthalmic applications | |
US20220370618A1 (en) | Polymer hydrogels for in vivo applications and methods for using and preparing same | |
US20040171044A1 (en) | Delivery of substances to cells | |
US20030147966A1 (en) | Nanoparticle delivery vehicle | |
Gohil et al. | Evaluation of enzymatically crosslinked injectable glycol chitosan hydrogel | |
Mauro et al. | RGD‐mimic polyamidoamine–montmorillonite composites with tunable stiffness as scaffolds for bone tissue‐engineering applications | |
Pötzinger et al. | Immobilization of plasmids in bacterial nanocellulose as gene activated matrix | |
Lai | Biodegradable in situ gelling delivery systems containing pilocarpine as new antiglaucoma formulations: effect of a mercaptoacetic acid/N-isopropylacrylamide molar ratio | |
US20220387597A1 (en) | Injectable intraocular microgel as drug delivery system, and hydrogel comprising same | |
JP2022522965A (ja) | 組換えラブリシン、並びにそれを使用するための組成物及び方法 | |
WO2003006068A1 (fr) | Therapie genique pour le syndrome d'oeil sec | |
US20030087850A1 (en) | Gene therapy for dry eye syndrome | |
CN113795590B (zh) | 前药组合物中药物浓度的量化方法 | |
WO2012135575A2 (fr) | Compositions et procédés pour introduction de macromolécules dans cellules | |
WO2000078357A2 (fr) | Pellicule d'acide hyalonurique et matrice pour transfert prolonge de genes | |
Lou et al. | Synthetic hydrogels as carriers in antisense therapy: preliminary evaluation of an oligodeoxynucleotide covalent conjugate with a copolymer of 1-vinyl-2-pyrrolidinone and 2-hydroxyethyl methacrylate | |
CN107530407A (zh) | 丙酰辅酶a羧化酶组合物及其用途 | |
KR20070017373A (ko) | 건조되고 응집된 히알루론산 생성물 | |
CN110845568B (zh) | 一种工程化组装蛋白聚糖及其制备方法和应用 | |
US12304934B2 (en) | Recombinant lubricins, and compositions and methods for using the same | |
US20160177277A1 (en) | Mutants of cocaine esterase | |
WO2025023216A1 (fr) | Procédé de production de tissu cellulaire tridimensionnel et tissu cellulaire tridimensionnel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |